Sector News

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

April 10, 2021
Life sciences

Piece by piece, Zimmer Biomet has been steadily laying the groundwork for its digital surgery platform—gathering clearances for robotic systems, developing smartphone apps for patients and setting up partnerships to gather the data showing it could all work together.

Now it’s connecting all the dots.

Zimmer has rolled out its ZBEdge suite, integrating its Rosa robot for total knee replacement procedures with separate surgical planning, joint alignment and navigation tools—as well as the company’s mymobility app, which uses the sensors in Apple Watch and iPhone to track a patient’s progress through pre- and post-operative exercises.

The ultimate goal is to take some of the guesswork out of medicine, Zimmer Biomet’s worldwide general manager of robotics, Liane Teplitsky, said in an interview late last year after being named one of 2020’s Fiercest Women in Life Sciences.

“We don’t yet have the big data to be able to do those kinds of analytics—and a lot of it is done by feel,” she said. “For example, a lot of surgeons will tell their patients, ‘We know you need a knee replacement, but you can decide when you want to have it.’”

The new suite aims to provide hospitals and ambulatory surgical centers with an overarching orthopedic product line that follows the patient before, during and after the procedure, and feed that information back into the operating room to help guide a surgeon’s decisions.

By using that information to construct a virtual copy of a prospective patient—built on a bedrock of hundreds of medical histories from people with similar conditions and anatomies, alongside the results of their surgery—physicians could be shown a way to deliver newly optimized treatments, Teplitsky said.

“We just don’t have the data to say if you have [the procedure] when you have this much pain, or when your gait has changed by this much, you will have a better outcome,” she said. “We just don’t have that information today—so being able to guide that will be a real game-changer.”

The company also aims to build out the program further over the course of the year, while taking the system on a traveling roadshow to demonstrate it to providers.

The company’s Rosa robot won its FDA clearance in 2019, itself an integration of surgeon-assisting hardware and three-dimensional software planning tools. Today versions of the platform are also used for minimally invasive brain and spine procedures, with the latter joining an upcoming spinout alongside Zimmer Biomet’s dental businesses.

by Conor Hale

Source: fiercebiotech.com

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.